Manufacturing Financial News

₹33,000 crore for its 33.47% stake and will only cede control if binding bids value the drugmaker at ₹1 trillion, according to one of the two people. “The latest discussions with Cipla promoters’ bankers regarding valuations and the premium to market price happened on Friday," said the first person, who added that Cipla’s promoters want a price of a little over ₹1,200 per share. Cipla’s shares ended trading at ₹1,180.50 on Wednesday, valuing the company at ₹95,300 crore.

If you have not bought your helmet yet, then you need to read this article where we share a list of the best Vega helmets in India. All of these helmets are up to the standards of the Bureau of Indian Standards (BIS) which means you can expect complete safety. Once you like a product, use the buying link given in the article to place your order.

By Lucia Mutikani

By Abigail Summerville

₹5,298.95 per share on BSE on Wednesday. (Refresh for more updates)"Exciting news! Mint is now on WhatsApp Channels

Chennai: Chocolate manufacturer and supplier LOTTE India has ramped up production at its factory in Tamil Nadu with an investment of Rs 185 crore. The facility, spread across 85,562 sq ft land in Nemam near here, would increase production of the company's range of Choco Pie.

Investing.com — U.S. futures rose Wednesday, rebounding after the previous session’s selloff with investors awaiting developments on a U.S. funding bill as well as future Federal Reserve's monetary policy.

Tata Power Renewable Energy Ltd (TPREL), a subsidiary of The Tata Power Company Limited, will set up a 41 MW captive solar plant at Thoothukudi, Tamil Nadu for TP Solar’s new greenfield 4.3 GW solar cell and module manufacturing facility located at Tirunelveli, Tamil Nadu. The captive plant will help generate 101 million units of electricity and offset around 72,000 metric tonnes of CO2 emissions annually. The solar project will be commissioned 12 months from the signing of the Project Development Agreement (PDA). TPREL has established TP Govardhan Creatives Limited, a specialized entity entrusted with the development, operation, and upkeep of this facility for TP Solar Ltd. TP Solar’s manufacturing plant is expected to start commercial production of cells and modules by FY 24-25.

Rana Gupta, MD, Manulife Investment Management, says over the last 10 years, a lot of reforms have happened basically by pivoting the economy from a higher deficit to a much higher savings economy, from more consumption incentives to more investment incentives. Even domestically, for the companies that were linked to those themes – a higher or average PE is all right. But if a company or sector is not linked to those tailwinds and is still trading at higher PE in this high interest rate environment, then a fair amount of caution will come in.” Interest rates are largely a function of how markets are valued and these have gone up quite significantly. So while we are very close to our 10-year averages when it comes to Indian market valuations, with the adjusted interest rate where the US 10-year bond yield is at 4.5% odd now,, how do you look at valuations? Should one look and adjust for those or are you believing that the larger valuation picture is looking decent? Interest rates are set by demand and supply of money and, of course, the central banks can influence and also set those interest rates. But broadly the question is whether with the global interest rates going up and Indian stock market trading above 10 years of the average valuation, we should reset the valuation benchmark in the light of higher global interest rates?

midcap stocks demonstrated their potential by surpassing their 50-day SMA. Let's explore the performance of these stocks. (Data Source: StockEdge) 1. Tata Elxsi Tata Elxsi Limited is a leading global design and technology services provider.

DTC likely to sign a contract for procuring electric buses within this week, an official said on Wednesday. The mohalla bus service, announced in the 2023-24 Delhi budget, aims to deploy shorter nine-metre electric buses to boost last-mile connectivity in areas with roads that have less width or are crowded. «We are likely to sign a contract with the e-bus manufacturers this week or early next week for procurement of buses.

₹152 crore from the share sale. Valiant Laboratories specialises in manufacturing Paracetamol as an Active Pharmaceutical Ingredient (API) or Bulk Drug. A manufacturing facility owned by Valiant Laboratories is located in Palghar, Maharashtra, India.

diamonds for two months starting from October 15 amid slowing global demand and rising inventories of domestic players. "...demand for loose polished diamonds and jewellery from large consuming economies such as the USA and China have been materially affected over the last many quarters, on the back of all-time highs of 2021 and 2022, with a visible slowdown in orders. «As a result, our country's exports have declined by 25 per cent during January-August, with a similar trend in September.

Toyota Motor plans to build a third car plant in India, expanding production capacity in the country for the first time in over a decade as its partnership with Suzuki Motor boosts domestic volumes, two sources said. The world's biggest car maker wants the plant to start with capacity of 80,000-120,000 vehicles a year, which could grow to around 200,000 over time, said one of the people who has direct knowledge of the plans. The plant's proposed initial capacity would expand Toyota's existing manufacturing capacity in India by as much as 30% from 400,000 units currently. Toyota has also begun development of a new sport utility vehicle (SUV) for the Indian market that would be launched in early 2026 and be an anchor product for the new factory, said the person and a third source briefed on the company's plans. The sources declined to be identified as the automaker has not disclosed the expansion plans. A representative for Toyota's India unit declined to comment. Toyota's India sales have soared due to a global partnership with Suzuki under which the two Japanese car makers take some vehicles originally developed by their partner, then tweak and sell under their own brands to fill out their product line-up. Cars originally from Maruti Suzuki's stable such as the Glanza hatchback and Urban Cruiser Hyryder SUV now account for 40% of Toyota's India sales. About two-thirds of Toyota's current production capacity is used by Maruti Suzuki to build vehicles for both car makers as part of their partnership. Toyota, known for its Fortuner SUV and Camry hybrid in India, told Reuters earlier in September it expects record domestic sales in 2023. The Japanese car maker is now aiming to have production capacity of 500,000

midcap stocks demonstrated their resilience by surpassing their 100-day SMA. Let's explore the performance of these stocks. (Data Source: StockEdge) 1. Astral Astral Limited is a leading manufacturer of pipes and fittings for plumbing and agricultural applications.

Hindustan Times, adding that a draft memorandum of understanding (MoU) has been finalised after negotiations between the two sides. Taipei is looking towards New Delhi to address the manpower shortage in key sectors such as manufacturing, including factories, construction projects, household workers, and agriculture and fisheries, the sources claimed.

hybrid cars because in the country, 75 per cent of the electricity is made from coal, according to R.C. Bhargava, the Chairman of Maruti Suzuki Ltd. He made the remarks while addressing the 50th National Management Convention organised by All India Management Association (AIMA). Bhargava said that the electric cars will not be clean until India gets at least 50 per cent of its electricity from renewable sources.

dirigiste industrial policy. So far Congress has authorised at least $80bn in place-based spending (according to the Brookings Institution, a think-tank), disbursed through a range of competitive grants. The biggest-ticket items include funding authorised in the CHIPS Act, passed last year to spur American semiconductor manufacturing.

McKinsey & Co has agreed to pay $230 million in its latest settlement to resolve lawsuits alleging it fueled a US opioid epidemic through its role advising drug manufacturers, according to court documents filed Tuesday. Thousands of lawsuits, brought by US local governments, schools, Native American communities, and parents on behalf of children born with withdrawal symptoms, accused McKinsey of strategizing with drug manufacturers to aggressively market prescription opioids «to maximize opioid revenues», the filings showed. McKinsey will pay $207 million to resolve claims by counties and municipalities, and $23 million to resolve claims by public school districts. Opioids are the main cause of drug overdose deaths in the United States, according to the US Centers for Disease Control and Prevention, with more than 75 percent of all drug overdose deaths in 2021 linked to them. McKinsey had already paid more than $640 million in 2021 to resolve lawsuits raised by 50 state attorneys-general over its work for bankrupt OxyContin maker Purdue Pharma and others. Tuesday's court filing said McKinsey had created and implemented marketing strategies for Purdue «before and after» the manufacturer's first guilty plea in 2007 relating to misbranding of OxyContin. The settlement still requires a judge's approval. McKinsey has consistently maintained its past work was lawful, but firm has said it ceased to advise clients on opioid-related business in 2019. «We did not adequately acknowledge the epidemic unfolding in our communities or the terrible impact of opioid misuse and addiction on millions of families across the country,» it said in a statement released in in 2020. «That is why last year (2019) we stopped doing any work

mid-cap stocks have once again proved their potential by outperforming the benchmark indices in 2023 by a huge margin. Mid-cap stocks have the potential to give high returns in a bullish market phase. Although individual stock performance is the primary reason behind this rally, another important contributing factor is the performance of the Indian economy and the rising importance of India as a key player in the global supply chain.

Valiant Laboratories IPO date: Valiant Laboratories IPO is opening for subscription today (Wednesday, September 27) and it will close on Tuesday, October 3. Valiant Laboratories specialises in manufacturing Paracetamol as an Active Pharmaceutical Ingredient (API) or bulk drug.